MIND MEDICINE MINDMED INC (MNMD)       3.44  0 (0%)

3.44  0 (0%)

CA60255C8850 - Common Stock

MIND MEDICINE MINDMED INC3.44

NASDAQ:MNMD (1/30/2023, 8:36:08 AM)0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 08-11 2022-08-11/amc Earnings (Next) 03-27 2023-03-27
Ins Owners 17.97% Inst Owners 6.33%
Market Cap 96.88M Shares 28.16M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 85.71
IPO 05-04 2015-05-04

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

MNMD Daily chart

Company Profile

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm is engaged in developing products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. The firm is developing a pipeline of drug candidates, targeting the serotonin, dopamine and acetylcholine systems. This specifically includes pharmaceutically optimized drug products derived from the psychedelic and empathogen drug classes, including lysergic acid diethylamide (LSD), R(-)-methylenedioxymethamphetamine (MDMA) and zolunicant, or 18-methoxycoronaridine (MC), a congener of ibogaine. The Company’s subsidiaries include Mind Medicine, Inc. (MindMed US), HealthMode, Inc., MindMed Pty Ltd., and MindMed GmbH.

Company Info

MIND MEDICINE MINDMED INC

1166 Alberni Steet, Suite 1604

Vancouver BRITISH COLUMBIA

P: 12122206633.0

Employees: 50

Website: https://mindmed.co/

MNMD News

News Image4 days ago - FinancialNewsMediaPsychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry

EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END

News Image4 days ago - FinancialNewsMedia.comPsychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry

/PRNewswire/ -- Even during the recent global supply chain problems, certain markets have continued to show growth. The psychedelic drugs markets is one of...

MNMD Twits

Here you can normally see the latest stock twits on MNMD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example